Stefan Diem

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Stefan Diem, Sabine Schmid, M. Krapf et al. · Lung Cancer · 2017 · 1K citations

Medicine, Immunology, Oncology +16

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

Fiamma Berner, David Bomze, Stefan Diem et al. · JAMA Oncology · 2019 · 393 citations · Full text

Life Sciences, Immunology, Oncology +17

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Stefan Diem, Benjamin Kasenda, Lavinia Spain et al. · British Journal of Cancer · 2016 · 308 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma

Daniel L. Morganstein, Zhuangming Marc Lai, Lavinia Spain et al. · Clinical Endocrinology · 2016 · 188 citations

Medicine, Endocrinology, Oncology +17

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

Omar Hasan Ali, Fiamma Berner, David Bomze et al. · European Journal of Cancer · 2018 · 183 citations · Full text

Life Sciences, Immunology, Oncology +17